Corporate Profile

Corporate Profile

Email page PDF view Print view Email Alert Social media sharing

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs. We believe that we are well positioned to compete successfully in these areas using our proprietary siRNA technology platform and immunotherapy agent, Samcyprone™. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.


$ 1.99

NASDAQ:RXII

Change
$ (0.06)  |  (3.12) %
Market Capital ($M)
13.03
Volume
18,357
Minimum 20 minute delay.

Investor Relations


Contact Information


Investor Relations
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com


Business Development
James Cardia, Ph.D.
508-929-3634
jcardia@rxipharma.com